Search Result

Results for "

antiasthmatic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (2) Apoptosis (4) Autophagy (4) DNA/RNA Synthesis (1) Endogenous Metabolite (2) Ferroptosis (6) GABA Receptor (1) Glucocorticoid Receptor (3) GLUT (2) HMG-CoA Reductase (HMGCR) (4) Interleukin Related (1) Isotope-Labeled Compounds (7) JNK (2) Leukotriene Receptor (7) Lipoxygenase (5) MDM-2/p53 (2) Mitophagy (4) NF-κB (3) Opioid Receptor (1) P2X Receptor (1) Phosphodiesterase (PDE) (2) Prostaglandin Receptor (4) Reactive Oxygen Species (2)
By Research Areas:	Cancer (19) Cardiovascular Disease (5) Endocrinology (3) Inflammation/Immunology (39) Metabolic Disease (6) Neurological Disease (7)

By Targets:

Amylases (2)

Apoptosis (4)

Autophagy (4)

DNA/RNA Synthesis (1)

Endogenous Metabolite (2)

Ferroptosis (6)

GABA Receptor (1)

Glucocorticoid Receptor (3)

GLUT (2)

HMG-CoA Reductase (HMGCR) (4)

Interleukin Related (1)

Isotope-Labeled Compounds (7)

JNK (2)

Leukotriene Receptor (7)

Lipoxygenase (5)

MDM-2/p53 (2)

Mitophagy (4)

NF-κB (3)

Opioid Receptor (1)

P2X Receptor (1)

Phosphodiesterase (PDE) (2)

Prostaglandin Receptor (4)

Reactive Oxygen Species (2)

By Research Areas:

Cancer (19)

Cardiovascular Disease (5)

Endocrinology (3)

Inflammation/Immunology (39)

Metabolic Disease (6)

Neurological Disease (7)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101427

Bamaquimast F 10126; L 0042	Others	Inflammation/Immunology
Bamaquimast (F 10126; L 0042) is a potent antiasthmatic agent .

HY-14164

Zileuton Maximum Cited Publications 13 Publications Verification A 64077; Abbott 64077	Lipoxygenase Ferroptosis	Inflammation/Immunology Cancer
Zileuton is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties.

HY-B1718

Choline theophyllinate 2 Publications Verification Oxtriphylline	Endogenous Metabolite	Inflammation/Immunology
Choline theophyllinate (Oxtriphylline) is a choline salt of theophylline with anti-asthmatic activity .

HY-U00409

Antiasthmatic Compound 1	Others	Inflammation/Immunology
Antiasthmatic Compound 1 is an antiasthmatic agent, which has the potential for allergic asthma treatment.

HY-W754020

Elbanizine	Others	Others
Elbanizine inhibits histamine, bradykinin, histamin-release from rat mast cells (IC₅₀ of 0.26 μM) and the IgE-mediated passive cutaneous anaphylaxis (PCA) reaction. Elbanizine exhibits antiallergic and antiasthmatic in guinea pig model .

HY-N1871

4-(2-Hydroxy-1-methoxyethyl)-1,2-benzenediol	Others	Inflammation/Immunology
4-(2-Hydroxy-1-methoxyethyl)-1,2-benzenediol is a phenylethanoid isolated from the stem bark of Syringa reticulate (Bl.) Hara (Oleaceae) with expectorant and antiasthmatic activity .

HY-U00258

Minocromil FPL59360	Others	Inflammation/Immunology
Minocromil (FPL59360) is a new *Anti-asthmatic* agent.

HY-116209

Pyrogallol triacetate NSC 24068	Others	Inflammation/Immunology
Pyrogallol triacetate (NSC 24068) is used as an antiasthmatic .

HY-163648

Suloxifen	Others	Inflammation/Immunology
Suloxifen is a thioketone compound, which exhibits anti-asthmatic efficacy .

HY-164012

Proxicromil	Others	Inflammation/Immunology
Proxicromil is a derivative of chromone. Proxicromil is an orally active anti-asthmatic agent, and exhibits no liver toxicity .

HY-U00412

Asthma relating compound 1	Others	Inflammation/Immunology
Asthma relating compound 1 is an anti-asthmatic agent candidate extracted from patent EP0295656A1.

HY-N1399

Androsin	Others	Inflammation/Immunology
Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth, with anti-asthmatic effects .

HY-B0774

Seratrodast 4 Publications Verification AA 2414	Ferroptosis JNK MDM-2/p53 Prostaglandin Receptor Reactive Oxygen Species	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity .

HY-14164R

Zileuton (Standard) A 64077 (Standard); Abbott 64077 (Standard)	Lipoxygenase Ferroptosis	Inflammation/Immunology Cancer
Zileuton (Standard) is the analytical standard of Zileuton. This product is intended for research and analytical applications. Zileuton is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties.

HY-14164S

Zileuton-d4	Isotope-Labeled Compounds Lipoxygenase Ferroptosis	Inflammation/Immunology Cancer
Zileuton-d₄ is the deuterium labeled Zileuton. Zileuton (A 64077) is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties[1][2].

HY-143890

MRS4738	P2X Receptor	Inflammation/Immunology
MRS4738 is a potent and high affinity P2Y14R antagonist. MRS4738 exhibits anti-hyperallodynic and antiasthmatic activity in vivo .

HY-133215

Zileuton sulfoxide	Lipoxygenase	Inflammation/Immunology
Zileuton sulfoxide is a sulfoxide derivative of Zileuton (HY-14164), a potent and selective inhibitor of lipoxygenase 5-LOX with anti-asthmatic properties .

HY-B0774R

Seratrodast (Standard)	Ferroptosis JNK MDM-2/p53 Prostaglandin Receptor Reactive Oxygen Species	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Seratrodast (Standard) is the analytical standard of Seratrodast. This product is intended for research and analytical applications. Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity .

HY-U00072

RS-601	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.

HY-17492

Zafirlukast 3 Publications Verification ICI 204219	Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-B1718R

Choline theophyllinate (Standard)	Endogenous Metabolite	Inflammation/Immunology
Choline theophyllinate (Standard) is the analytical standard of Choline theophyllinate. This product is intended for research and analytical applications. Choline theophyllinate (Oxtriphylline) is a choline salt of theophylline with anti-asthmatic activity .

HY-14164S1

Zileuton-13C2,15N A 64077-¹³C₂,¹⁵N; Abbott 64077-¹³C₂,¹⁵N	Lipoxygenase Ferroptosis Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Zileuton- ¹³C₂, ¹⁵N is ¹⁵N and ¹³C labeled Zileuton (HY-14164). Zileuton is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties.

HY-N1399R

Androsin (Standard)	Others	Inflammation/Immunology
Androsin (Standard) is the analytical standard of Androsin. This product is intended for research and analytical applications. Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth, with anti-asthmatic effects .

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-17492R

Zafirlukast (Standard)	Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S

Zafirlukast-d7	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast-d₇ is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects[1][2].

HY-15234

Fluticasone furoate	Glucocorticoid Receptor	Inflammation/Immunology
Fluticasone furoate is a topical, intranasal, enhanced-affinity synthetic trifluorinated corticosteroid with a K_d of 0.3 nM. Fluticasone furoate has potent anti-inflamatory and anti-asthmatic activity, and low systemic exposure. Fluticasone furoate has the potential for allergic rhinitis treatment .

HY-17492S3

Zafirlukast-d6 ICI 204219-d₆	Leukotriene Receptor Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Zafirlukast-d₆ is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-B0462D

(S)-Azelastine (+)-Azelastine	Others	Inflammation/Immunology
(S)-Azelastine ((+)-Azelastine) is an antihistamine with antiallergic and antiasthmatic activity. (S)-Azelastine has been shown to downregulate H1R, M1R, and M3R levels. (S)-Azelastine also has the property of inhibiting HNEpC proliferation .

HY-17492S1

Zafirlukast-13C,d3 ICI 204219-¹³C,d₃	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast- ¹³C,d₃ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S2

Zafirlukast-13C,d6 ICI 204219-¹³C,d₆	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast- ¹³C,d₆ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-117616

Laurotetanine (+)-Laurotetanine	NF-κB	Cancer
Laurotetanine ((+)-Laurotetanine) is an potent and orally active isoquinoline alkaloid and could be extracted from the roots of Litsea cubeba (Lour.) Pers. Laurotetanine exerts an anti-asthmatic effect by inhibition of IgE, histamine, and inflammatory reactions via down-regulating MUC5AC and NF-κB signaling pathways .

HY-N7437

Akuammidine	Opioid Receptor DNA/RNA Synthesis	Neurological Disease Inflammation/Immunology
Akuammidine, isolated from the seeds of Picralima nitida, shows a preference for μ-opioid binding sites with K_i values of 0.6, 2.4 and 8.6 μM at μ-, σ- and κ-opioid binding sites, respectively. Akuammidine possesses anti-inflammatory and anti-asthmatic properties .

HY-W074888

N-Lauroyl-L-glutamic acid	Others	Inflammation/Immunology
N-Lauroyl-L-glutamic acid is an amino acid derivative with anti-asthmatic activity. N-Lauroyl-L-glutamic acid has been found to improve asthma symptoms in studies. The potential application of N-Lauroyl-L-glutamic acid is mainly focused on the suppression of respiratory diseases. N-Lauroyl-L-glutamic acid may help improve the quality of life of patients .

HY-131340

LASSBio-1632	Phosphodiesterase (PDE)	Inflammation/Immunology
LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion .

HY-15234S

Fluticasone furoate-d3	Isotope-Labeled Compounds Glucocorticoid Receptor	Inflammation/Immunology
Fluticasone furoate-d₃ is deuterium labeled Fluticasone furoate. Fluticasone furoate is a topical, intranasal, enhanced-affinity synthetic trifluorinated corticosteroid with a Kd of 0.3 nM. Fluticasone furoate has potent anti-inflamatory and anti-asthmatic activity, and low systemic exposure. Fluticasone furoate has the potential for allergic rhinitis treatment[1][2].

HY-15234R

Fluticasone furoate (Standard)	Glucocorticoid Receptor	Inflammation/Immunology
Fluticasone furoate (Standard) is the analytical standard of Fluticasone furoate. This product is intended for research and analytical applications. Fluticasone furoate is a topical, intranasal, enhanced-affinity synthetic trifluorinated corticosteroid with a K_d of 0.3 nM. Fluticasone furoate has potent anti-inflamatory and anti-asthmatic activity, and low systemic exposure. Fluticasone furoate has the potential for allergic rhinitis treatment .

HY-17002

Suplatast (Tosilate) 1 Publications Verification IPD 1151T	Interleukin Related	Inflammation/Immunology
Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity .

HY-123801

MIDD0301 GL-II-93	GABA Receptor	Others
MIDD0301 (GL-II-93) is an orally effective, anti-asthmatic positive allosteric modulator of GABA_A receptor. MIDD0301 had no significant adverse immune reactions at repeated doses and was better than Prednisone (HY-B0214). MIDD0301 relaxes histamine contractions in guinea pig and human tracheal smooth muscle for the study of bronchial systolic diseases .

HY-B0144A

Pitavastatin 5+ Cited Publications NK-104	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-B0144B

Pitavastatin sodium NK-104 sodium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-B0144

Pitavastatin Calcium 5+ Cited Publications NK-104 hemicalcium; Pitavastatin hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-N1860

3-O-Methylquercetin	Phosphodiesterase (PDE)	Inflammation/Immunology
3-O-Methylquercetin (3-MQ) is a major component from the plant Rhamnus nakaharai and has antiviral activity and potential antiasthmatic efficacy. 3-O-Methylquercetin inhibits total cAMP and cGMP-phosphodiesterase (PDE). The IC₅₀ values of 3-O-Methylquercetin (3-MQ) against PDE1-PDE5 are in the range of 1.6-86.9 μM. 3-O-Methylquercetin is a non-competitive inhibitor of PDE2 and a competitive inhibitor of PDE4 .

HY-N0668

Rubusoside 2 Publications Verification	GLUT Amylases NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .

HY-B0144R

Pitavastatin Calcium (Standard)	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (Calcium) (Standard) is the analytical standard of Pitavastatin (Calcium). This product is intended for research and analytical applications. Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-N0668R

Rubusoside (Standard)	GLUT Amylases NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .

HY-167939

(R)-Bambuterol	Others	Inflammation/Immunology
(R)-Bambuterol is a β2-receptor agonist with anti-asthmatic and colitis-improving activity. (R)-Bambuterol is indicated for the treatment of asthma and chronic obstructive pulmonary disease and has the advantage of a once-daily dosing and a favorable side effect profile. (R)-Bambuterol significantly reduced disease severity in a mouse model of colitis, more effectively than (RS)-Bambuterol or (S)-Bambuterol. (R)-Bambuterol can significantly reduce the levels of inflammatory cytokines and reduce the infiltration of macrophages in mice with colitis. (R)-Bambuterol also increases β2-adrenoceptor levels and reduces the expression of IL-6, IL-17 and other related proteins in colon tissue in a dose-dependent manner .

HY-118156

L-699333	Others	Others
L-699333 is a 5-lipoxygenase (5-LO) inhibitor belonging to the thieno[2,3,4-cd]indole class. This compound has a 2-ethoxybutyric acid side chain and is a potent inhibitor of the biosynthesis of 5-HPETE and LTB4 produced from human 5-LO, with ICm values of 22 nM, 7 nM, and 3.8 pM for human neutrophils and whole blood, respectively. L-699333 has shown anti-inflammatory and antiasthmatic effects in a variety of animal models, including rat pleurisy models, antigen-induced wheezing models, and awake macaque and sheep asthma models. Its inhibition of 5-LO is highly selective, with higher ICm values or stronger competitive inhibition in FLAP binding assays compared to inhibition of human 15-LO, porcine 12-LO, and ram epididymal cyclooxygenase. The racemic enantiomer 14g of L-699333 is the most potent enantiomer to date, with inhibitory effects similar to those of the known MK-0591, which has been shown in clinical trials to inhibit the biochemical effects of LTB4 biosynthesis in vitro and LTE4 excretion in urine.

Cat. No.	Product Name	Category	Target	Chemical Structure